Unibest
← Back to patent-cliff list

Icerguastat

Tier C — Watch / trade

Icerguastat

Medical Research Council
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:PPP1R15A, NMDAR

Indications (approved):Amyotrophic lateral sclerosis, 夏科-马里-图斯病

Regional status

US
-
EU
Phase II
2022-12-02
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 1 · Total yield /
Sephin-1-00189-98-5Sephin-1-002 free79-17-4API · Icerguastat
CodeCAS No.Intermediate
Sephin-1-00189-98-52-chlorobenzaldehyde
Sephin-1-002 free79-17-4-

Frequently asked questions

What are the approved indications of Icerguastat?

Approved indications include: Amyotrophic lateral sclerosis, 夏科-马里-图斯病.

When does the Icerguastat patent expire?

No public expiry year is available for Icerguastat yet; this page updates once verified.

How many synthesis routes are recorded for Icerguastat?

1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Icerguastat intermediates?

All intermediates in Icerguastat routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Icerguastat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-03